BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. ACN
5. IBM
6. SPY
7. TSLA
8. DPZ
9. NVDA
10. PRIM

Go back to BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

BioMarin Pharma (BMRN) Announces FDA Committee Review of Drisapersen NDA in DMD Amenable to Exon 51 Skipping

October 15, 2015 7:56 AM EDT

BioMarin Pharma (NASDAQ: BMRN) announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the New Drug Application (NDA) for drisapersen. The FDA is currently reviewing drisapersen for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The advisory committee will review drisapersen data included in a new drug application (NDA) during a meeting on November 24, 2015.

Duchenne muscular dystrophy is a deadly, progressive muscle disorder with limited treatment options that affects mostly boys and young... More